0. DOCID:29369 SCORE: 0.00110111596973868
DOCNO: 14769524
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: isolation & purification
AUTHOR: Karine Rollot K
AUTHOR: Jean David Albert JD
AUTHOR: Stéphanie Werner S
AUTHOR: Pierre Tattevin P
AUTHOR: Isabelle Cozic I
AUTHOR: Aleth Perdriger A
AUTHOR: Gérard Chalès G
AUTHOR: Pascal Guggenbuhl P
AFFILIATION: Rheumatology Department, CHU Hôpital Sud 16, Boulevard de Bulgarie, 35056 Rennes cedex 2, France.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Joint, bone, spine : revue du rhumatisme.
COUNTRY: France
TITLE: Campylobacter fetus septic arthritis revealing a malignancy.
PUBDATE: 20040101
Campylobacter fetus is a rare cause of bone and joint infection. We report a new case in a patient who also had endocarditis due to the same organism. This type of infection usually occurs in immunocompromised hosts. Investigations in our patient found a cancer of the prostate.


1. DOCID:31887 SCORE: 0.000602281889643255
DOCNO: 15340416
AUTHOR: Steven A Rosenberg SA
AUTHOR: James C Yang JC
AUTHOR: Nicholas P Restifo NP
AFFILIATION: Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892-1502, USA. sar@mail.nih.gov
PUBTYPE: Journal Article
JOURNALTITLE: Nature medicine.
COUNTRY: United States
TITLE: Cancer immunotherapy: moving beyond current vaccines.
PUBDATE: 20040901
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.


2. DOCID:29710 SCORE: 0.000559081441338509
DOCNO: 15549090
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
AUTHOR: Charles Sawyers C
AFFILIATION: Howard Hughes Medical Institute, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, 10833 LeConte Avenue, Los Angeles, California 90095, USA. csawyers@mednet.ucla.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature.
COUNTRY: England
TITLE: Targeted cancer therapy.
PUBDATE: 20041101
Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Complex networks of regulatory factors, the tumour microenvironment and stress signals, such as those resulting from damaged DNA, dictate whether cancer cells proliferate or die. Recent progress in understanding the molecular changes that underlie cancer development offer the prospect of specifically targeting malfunctioning molecules and pathways to achieve more effective and rational cancer therapy.


3. DOCID:30843 SCORE: 0.000559062212416127
DOCNO: 14577822
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Prosthesis Design
QUALIFIER: instrumentation
QUALIFIER: therapy
AUTHOR: Filiz Keyf F
AUTHOR: Nesrin Sahin N
AUTHOR: Yavuz Aslan Y
AFFILIATION: Department of Prosthodontics at Faculty of Dentistry, Hacettepe University, Ankara, Turkey. dkeyf@e-kolay.net
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association.
COUNTRY: United States
TITLE: Alternative impression technique for a speech-aid prosthesis.
PUBDATE: 20031101
OBJECTIVE: Prosthetic treatment for speech disorders attributable to surgically acquired soft palate defects are introduced. CASE: A patient who underwent soft palate resection for cancer is presented. The resected portion of the soft palate was confined to the posterior segments. A prosthesis with a speech bulb was adapted to the patient. CONCLUSION: Excellent restoration of speech and improvement of velopharyngeal function was achieved following placement of the special prosthesis.


4. DOCID:31189 SCORE: 0.000559055891984326
DOCNO: 14698790
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analogs & derivatives
QUALIFIER: pharmacokinetics
QUALIFIER: metabolism
QUALIFIER: pharmacokinetics
QUALIFIER: metabolism
QUALIFIER: metabolism
AUTHOR: C J Smith CJ
AUTHOR: W A Volkert WA
AUTHOR: T J Hoffman TJ
AFFILIATION: Radiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nuclear medicine and biology.
COUNTRY: England
TITLE: Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update.
PUBDATE: 20031101
The gastrin releasing peptide (GRP) receptor is becoming an increasingly attractive target for development of new radiolabeled peptides with diagnostic and therapeutic potential. The attractiveness of the GRP receptor as a target is based upon the functional expression of GRP receptors in several tumors of neuroendocrine origin including prostate, breast, and small cell lung cancer. This concise review outlines some of the efforts currently underway to develop new GRP receptor specific radiopharmaceuticals by employing a variety of radiometal chelation systems.


5. DOCID:30206 SCORE: 0.000559048531170889
DOCNO: 11990853
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Cell Transformation, Neoplastic
QUALIFIER: metabolism
QUALIFIER: physiopathology
AUTHOR: Mikala Egeblad M
AUTHOR: Zena Werb Z
AFFILIATION: Department of Anatomy, University of California at San Francisco, 94143-0452, USA. egeblad@itsa.ucsf.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: New functions for the matrix metalloproteinases in cancer progression.
PUBDATE: 20020301
Matrix metalloproteinases (MMPs) have long been associated with cancer-cell invasion and metastasis. This provided the rationale for clinical trials of MMP inhibitors, unfortunately with disappointing results. We now know, however, that the MMPs have functions other than promotion of invasion, have substrates other than components of the extracellular matrix, and that they function before invasion in the development of cancer. With this knowledge in hand, can we rethink the use of MMP inhibitors in the clinic?


6. DOCID:29356 SCORE: 0.000559047850192689
DOCNO: 15542423
AUTHOR: Michael R Freeman MR
AFFILIATION: Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, Enders Research Laboratories, Suite 1161, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. michael.freeman@childrens.harvard.edu
PUBTYPE: Comment
PUBTYPE: Journal Article
JOURNALTITLE: Cancer cell.
COUNTRY: United States
TITLE: HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?
PUBDATE: 20041101
In this issue of Cancer Cell, Mellinghoff et al. (2004) demonstrate that a small molecule inhibitor of the EGF receptor (EGFR) and the HER2/ErbB2/c-Neu kinase blocks signaling to the androgen receptor by a mechanism that involves HER2/HER3 heterodimerization. Surprisingly, the EGFR is peripheral to this signaling mechanism. These results have implications for the design of targeted therapy for hormone-refractory prostate cancer.


7. DOCID:31192 SCORE: 0.000559045354773759
DOCNO: 14571419
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: secondary
QUALIFIER: therapeutic use
QUALIFIER: pathology
AUTHOR: Theresa A Guise TA
AUTHOR: John M Chirgwin JM
AFFILIATION: Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in oncology.
COUNTRY: United States
TITLE: Role of bisphosphonates in prostate cancer bone metastases.
PUBDATE: 20031001
Bisphosphonate inhibitors of bone resorption have a variety of positive actions against prostate cancer cells in vitro and in preclinical animal models. In patients, they can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. The preclinical and clinical data to support this are reviewed here. Further clinical trials are required to determine whether bisphosphonates decrease tumor burden or increase patient survival or quality of life, and whether such adjuvant treatments will be cost-effective.


8. DOCID:29490 SCORE: 0.000559041627469427
DOCNO: 14740968
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiography
QUALIFIER: radiography
QUALIFIER: radiography
QUALIFIER: standards
QUALIFIER: standards
AUTHOR: Michael T Modic MT
AUTHOR: Nancy Obuchowski N
AFFILIATION: Division of Radiology, The Cleveland Clinic Foundation, OH 44195, USA. modicm1@ccf.org
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cleveland Clinic journal of medicine.
COUNTRY: United States
TITLE: Whole-body CT screening for cancer and coronary disease: does it pass the test?
PUBDATE: 20040101
Even though whole-body CT scanning is being marketed directly to patients and they are starting to demand it, does it meet the standards of a good screening test for cancer and coronary artery disease? This article is a step-by-step, disease-specific discussion of the characteristics of a good screening test, and whether whole-body CT scanning meets these standards.


9. DOCID:28501 SCORE: 0.000559038336747716
DOCNO: 16422359
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: ultrasonography
AUTHOR: Fethi Attyaoui F
AUTHOR: Mohamed Hmidi M
AUTHOR: Ghassen Hafsia G
AUTHOR: Yassine Nouira Y
AUTHOR: Ali Horchani A
AFFILIATION: Service d'Urologie, Hôpital La Rabta, Tunis.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: La Tunisie médicale.
COUNTRY: Tunisia
TITLE: [Transrectal ultrasound in the diagnosis of prostate cancer]
PUBDATE: 20051101
Transrectal ultrasound is an important tool in detection and management of prostate cancer. Its role is to identify and characterize focal lesions before capsular invasion and metastases and to guide biopsy of the prostate. In this paper, we present a overview of the state of trans-rectal ultrasound imaging in prostate cancer.


10. DOCID:28584 SCORE: 0.000559038336561368
DOCNO: 16282314
OWNER: NLM
STATUS: In-Process
AUTHOR: Benedito Borges da Silva BB
AUTHOR: Lina G Dos Santos LG
AUTHOR: Pedro Vitor L Costa PV
AUTHOR: Cleicilene Gomes Pires CG
AUTHOR: Anatole Santos Borges AS
AFFILIATION: Department of Gynecology and Department of Pathology, Federal University of Piauí, Teresina, Piauí, Brazil. beneditoborges@globo.com
PUBTYPE: Journal Article
JOURNALTITLE: The American journal of tropical medicine and hygiene.
COUNTRY: United States
TITLE: Primary tuberculosis of the breast mimicking carcinoma.
PUBDATE: 20051101
This report describes a well-documented case of primary, nodular-form tuberculosis of the breast that mimicked cancer in a 73-year-old patient. This is a disease that rarely affects the breast.


11. DOCID:30471 SCORE: 0.000559038142355553
DOCNO: 16340844
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: P Bonnette P
AFFILIATION: Hôpital Foch, Service de Chirurgie thoracique, 40 rue Worth, Suresnes, France.
PUBTYPE: Journal Article
JOURNALTITLE: Revue des maladies respiratoires.
COUNTRY: France
TITLE: [Lymph node clearance.]
PUBDATE: 20051201
The goal of mediastinal sampling or a radical lymph node resection after lung cancer resection is to correctly stage the illness to enable a more accurate assessment of prognosis. Metastasis to mediastinal nodes may be encountered even in small peripheral T1 tumours. Radical lymph node resection often uncovers metastases that would have been missed by mediastinal sampling alone. The morbidity associated with radical node resection is very low, and long term survival appears to be improved, compared with node sampling. At present, lymph node staging has little influence on the choice of adjuvant treatments.


12. DOCID:30894 SCORE: 0.000559038140740536
DOCNO: 16204992
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug effects
QUALIFIER: pharmacology
QUALIFIER: chemistry
AUTHOR: Atchara Tempeam A
AUTHOR: Nopporn Thasana N
AUTHOR: Chitkavee Pavaro C
AUTHOR: Wongsatit Chuakul W
AUTHOR: Pongpun Siripong P
AUTHOR: Somsak Ruchirawat S
AFFILIATION: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
PUBTYPE: Journal Article
JOURNALTITLE: Chemical & pharmaceutical bulletin.
COUNTRY: Japan
TITLE: A new cytotoxic daphnane diterpenoid, rediocide G, from Trigonostemon reidioides.
PUBDATE: 20051001
Rediocide G (7), a new daphnane diterpenoid, was isolated from the roots of Trigonostemon reidioides (Euphorbiaceae), together with two congeners, rediocide A and rediocide B, (+)-syringaresinol, scopoletin, tomentin and stigmasterol. The structure of the new natural product was elucidated by comparison of its NMR and mass spectral data with those of previously known rediocides and confirmed by extensive 2D NMR spectral analysis. Rediocide G (7) was found to be cytotoxic to various cancer cell lines.


13. DOCID:31135 SCORE: 0.00055903813990197
DOCNO: 16274269
AUTHOR: Joseph C Hsieh JC
AUTHOR: Maciej S Lesniak MS
AFFILIATION: Section of Neurosurgery, The University of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637, USA. jchsieh@surgery.bsd.uchicago.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Expert review of neurotherapeutics.
COUNTRY: England
TITLE: Surgical management of high-grade gliomas.
PUBDATE: 20051101
High-grade gliomas, in particular anaplastic astrocytoma and glioblastoma multiforme, represent two of the most devastating forms of brain cancer. In spite of the poor prognosis, new treatments and emerging therapies are making an impact on this disease. This review discusses the role of the surgical management of high-grade gliomas and provides an overview of the currently available therapies which depend on surgical intervention. At the same time, cutting-edge clinical trials for patients with malignant brain tumors are reviewed to provide further insights into potential future therapies.


14. DOCID:30349 SCORE: 0.000558988901103278
DOCNO: 15548050
OWNER: NLM
STATUS: In-Process
AUTHOR: Randell C Clevenger RC
AUTHOR: Brian S J Blagg BS
AFFILIATION: Department of Medicinal Chemistry and The Center for Protein Structure and Function, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, KS 66045-7562, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Organic letters.
COUNTRY: United States
TITLE: Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide.
PUBDATE: 20041101
A chimera composed of the natural products radicicol and geldanamycin has been prepared through an amide linkage connecting the resorcinol moiety of radicicol to the quinone ring of geldanamycin. The inhibitory activity of these compounds was determined by their ability to inhibit Hsp90's inherent ATPase activity along with degradation of the Hsp90 client protein, HER-2 in MCF-7 breast cancer cells. [reaction: see text]